NASDAQ:ABAX - Abaxis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$83.00
Today's Range$83.00 - $83.00
52-Week Range$43.66 - $83.98
VolumeN/A
Average Volume167,754 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.

Receive ABAX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500

Debt

Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A

Profitability

Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A

Miscellaneous

Employees656
OptionableOptionable

Abaxis (NASDAQ:ABAX) Frequently Asked Questions

What is Abaxis' stock symbol?

Abaxis trades on the NASDAQ under the ticker symbol "ABAX."

How often does Abaxis pay dividends? What is the dividend yield for Abaxis?

Abaxis declared a quarterly dividend on Thursday, April 26th. Investors of record on Friday, June 1st will be paid a dividend of $0.18 per share on Friday, June 15th. This represents a $0.72 annualized dividend and a yield of ∞. The ex-dividend date is Thursday, May 31st. This is a positive change from Abaxis's previous quarterly dividend of $0.16. View Abaxis' Dividend History.

How will Abaxis' stock buyback program work?

Abaxis announced that its board has initiated a share buyback plan on Wednesday, October 25th 2017, which permits the company to repurchase $21,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

How were Abaxis' earnings last quarter?

Abaxis Inc (NASDAQ:ABAX) issued its quarterly earnings data on Thursday, April, 26th. The medical research company reported $0.42 EPS for the quarter, beating the Zacks' consensus estimate of $0.32 by $0.10. The medical research company earned $67.90 million during the quarter, compared to the consensus estimate of $66.02 million. The firm's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 EPS. View Abaxis' Earnings History.

What price target have analysts set for ABAX?

5 brokerages have issued 12 month price targets for Abaxis' stock. Their predictions range from $48.00 to $65.00. On average, they anticipate Abaxis' share price to reach $58.3333 in the next year. View Analyst Price Targets for Abaxis.

What is the consensus analysts' recommendation for Abaxis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abaxis in the last year. There are currently 1 sell rating and 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Abaxis.

Has Abaxis been receiving favorable news coverage?

News stories about ABAX stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Abaxis earned a news impact score of 2.8 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the near term.

Who are some of Abaxis' key competitors?

Who are Abaxis' key executives?

Abaxis' management team includes the folowing people:
  • Mr. Clinton H. Severson, Chairman & CEO (Age 70)
  • Mr. Donald P. Wood, Pres & COO (Age 66)
  • Mr. Ross Taylor Jr., CFO, VP of Fin. & Sec. (Age 55)
  • Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
  • Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)

How do I buy shares of Abaxis?

Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abaxis' official website?

The official website for Abaxis is http://www.abaxis.com.

How can I contact Abaxis?

Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]


MarketBeat Community Rating for Abaxis (NASDAQ ABAX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  316 (Vote Underperform)
Total Votes:  520
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel